Events and costs (€, 2013).

<p>Total number of events of symptomatic (recurrent) DVT, symptomatic (recurrent) non-fatal PE, bleeding complications and related costs from societal perspective within a hypothetical patient population of 1,000 subjects receiving dabigatran and VKA for 180 days (base case analysis).</p><p>VKA: vitamin-K antagonist; VTE: venous thromboembolism; DVT: deep venous thrombosis; PE: pulmonary embolism: CRNM: clinically relevant non-major; INR, international normalized ratio.</p><p>¹Until the end of the post-treatment period</p><p>²First occurrence of primary efficacy endpoint</p><p>³During double-dummy period</p><p>⁴Statistically significant differences between VKA and dabigatran</p><p>⁵Productivity losses by those 50% of the patients being 64 years-of-age and younger.</p><p>Events and costs (€, 2013).